Get the Stockscreener App
60.56
0.35%
-0.21
After Hours:
60.65
0.09
+0.15%
Xenon Pharmaceuticals Inc stock is traded at $60.56, with a volume of 628.81K.
It is down -0.35% in the last 24 hours and down -7.43% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$60.77
Open:
$60.77
24h Volume:
628.81K
Relative Volume:
0.48
Market Cap:
$5.86B
Revenue:
$7.50M
Net Income/Loss:
$-383.17M
P/E Ratio:
-12.87
EPS:
-4.7048
Net Cash Flow:
$-307.84M
1W Performance:
-2.89%
1M Performance:
-7.43%
6M Performance:
+35.21%
1Y Performance:
+55.92%
1-Day Range:
$60.00
$61.05
1-Week Range:
$59.27
$64.93
52-Week Range:
$35.60
$72.66
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
60.56 | 5.78B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Bank of America Corp DE Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon (XENE) Today: Ends Down by 4.16% at $59.73 for the Current Session; Technical Setup: Support at $56.74 and Resistance at $62.72 Frame the Range under the Current SnapshotMcClellan Oscillator - Vinanet
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript - AOL.com
Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors? - simplywall.st
Xenon Pharmaceuticals (XENE) Holds Steady at $62.36 as Shares Consolidate Below Key ResistanceIV Rank - vinanet.vn
TimesSquare Capital Management LLC Purchases Shares of 451,593 Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) Could Be 23% Undervalued As Epilepsy Growth Narrative Holds - Sahm
Xenon Pharmaceuticals (XENE) Pulls Back 2.93% as Shares Approach Critical SupportCall Wall - vinanet.vn
Xenon Pharmaceuticals Independent Director Steven Gannon Sells 84% Of Holding - simplywall.st
Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals (XENE) Insider Sells 10,000 Shares; Direct - GuruFocus
(XENE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) Director Sells 10,000 Shares of Stock - MarketBeat
Xenon Pharmaceuticals (XENE) director sells 10,000 common shares at $64 - Stock Titan
Xenon Pharmaceuticals Insider Sold Shares Worth $640,550, According to a Recent SEC Filing - marketscreener.com
Xenon Pharmaceuticals Director Sold Shares Worth Over $640K - TradingView
Seller for XENE (NASDAQ: XENE) plans 10,000-share common stock sale - Stock Titan
Wellington group discloses 1.47% Xenon Pharmaceuticals (XENE) stake for advisory clients - Stock Titan
Xenon Pharmaceuticals (NASDAQ:XENE) Presents High-Quality Technical Breakout Setup - ChartMill
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity (XENE) - Seeking Alpha
HC Wainwright Issues Positive Outlook for XENE Earnings - MarketBeat
Xenon Pharmaceuticals Inc. (XENE): Analyst Consensus Highlights 26.65% Potential Upside - DirectorsTalk Interviews
H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy - Investing.com
H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Brokers Issue Forecasts for XENE Q1 Earnings - MarketBeat
Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
FDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals (XENE) - webull.com
Xenon Pharmaceuticals Stock Price Forecast. Should You Buy XENE? - StockInvest.us
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $81 to $90 - Moomoo
H.C. Wainwright Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $74 - Moomoo
XENE Maintained by RBC Capital -- Price Target Lowered to $81.00 - GuruFocus
Xenon Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Wedbush Adjusts PTon Xenon Pharmaceuticals to $71 From $63, Maintains Outperform Rating - Moomoo
Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says - marketscreener.com
Xenon Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $81.21, Implies 26% Upside - TradingView
FMR LLC (XENE) discloses 9.96M-share, 10.3% holding in Xenon Pharmaceuticals - Stock Titan
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus - Yahoo Finance
RBC Adjusts Xenon Pharmaceuticals PT to $81 From $82, Maintains Outperform Speculative Risk Rating - marketscreener.com
Xenon Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE - marketbeat.com
Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results - MarketBeat
Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ... - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlig - GuruFocus
XENON PHARMACEUTICALS INC. : WEDBUSH RAISES TARGET PRICE TO $71 FROM $63 - Bitget
XENE Advances Pipeline with NDA Submission Plans Amid High Price-to-Sales Valuation - GuruFocus
Xenon Pharmaceuticals Q2 Loss Widens - marketscreener.com
Earnings Flash (XENE) Xenon Posts Q2 Loss Per Share $1.11, vs. FactSet Est of $1.14 Loss - marketscreener.com
Xenon Pharmaceuticals Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Xenon Pharmaceuticals Inc. Q2 2026: Revenue $0 EPS $(1.11) — 10-Q Summary - TradingView
Xenon Pharmaceuticals Inc. R (XP0.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):